Paper-based diagnostic tests have revolutionized access to rapid testing, particularly with the advent of tests like COVID-19 assays. However, these tests have traditionally provided a binary outcome – either a yes or no answer. At a recent talk hosted by the American Chemical Society Division of Biochemistry and Chemical Biology, Kimberly Hamad-Schifferli from the University of Massachusetts Boston unveiled a groundbreaking approach to expand the capabilities of paper tests, enabling the detection of a wider array of diseases, including emerging ones.
Hamad-Schifferli’s team is at the forefront of developing paper tests for diseases like flaviviruses and coronaviruses. Their most recent innovation involves a test that can pinpoint different variants of the SARS-CoV-2 virus, demonstrating the versatility of this new method. By harnessing the cross-reactivity of antibodies – which can recognize multiple similar targets – the team has devised a test that moves beyond the conventional yes or no readout, offering a nuanced “fingerprint” analysis among a spectrum of patterns.
In this innovative approach, antibodies on the paper tests are linked to gold nanoparticles, imparting a distinctive deep red hue to the test. The analysis technique employed by Hamad-Schifferli’s group resembles chemical olfaction, where patterns are deciphered and categorized without prior knowledge of their identity. This method proves especially valuable in situations where costly DNA sequencing is inaccessible, yet healthcare providers urgently require information about the specific virus present. By leveraging existing antibodies, these tests offer a swift and cost-effective alternative for identifying new viruses, likened to “raiding the pantry” for available resources.
The implications of this novel testing method are profound. Instead of solely confirming the presence or absence of a particular virus, these tests offer a more sophisticated approach by analyzing patterns and comparing them against known disease profiles. This not only enhances diagnostic accuracy but also accelerates the identification of new viral strains, crucial for swift public health responses. By broadening the scope of paper tests beyond a binary output, Hamad-Schifferli’s work opens up new possibilities for versatile and efficient diagnostics in diverse settings, from healthcare facilities to resource-limited regions.
- The innovative approach to paper diagnostic tests developed by Hamad-Schifferli’s team utilizes the cross-reactivity of antibodies to enable a nuanced analysis of disease patterns.
- By moving beyond the traditional yes or no readout, these tests provide a “fingerprint” approach that enhances diagnostic accuracy and expedites the identification of emerging viral strains.
- Leveraging existing antibodies attached to gold nanoparticles, this method offers a cost-effective alternative to DNA sequencing, making it accessible in various healthcare settings.
- The ability to swiftly identify new viruses using this novel testing approach highlights its potential for facilitating rapid responses to public health crises and expanding diagnostic capabilities in resource-limited environments.
Read more on cen.acs.org